Madison, WI. September 30th, 2016.


Cellular Logistics has received a $50,000 commercialization grant from the Wisconsin Innovation Initiative. The Company will use the funds to progress early development efforts including a cardiac therapeutic and a regenerative medicine cell delivery platform. Co-Founder Eric Schmuck stated: “We are thrilled to receive this grant from Wi2. Wi2 is an innovative organization furthering life science commercialization activities in Wisconsin. Cellular Logistics is honored to be one of the companies identified by Wi2 as a high-potential life science venture.”


About Cellular Logistics: Cellular Logistics is an early stage life science venture commercializing innovations developed at The Wisconsin Institute for Medical Research (WIMR) at University of Wisconsin-Madison. The Company is developing an acellular biomaterial as a stand-alone therapeutic for cardiac and tissue vascularization applications. The material also provides a cell delivery mechanism for regenerative medicine therapeutics.


About the Wisconsin Innovation Initiative: The Wisconsin Technology Innovation Initiative, Inc. (Wi2) is a private, 501(c)(3) corporation committed to cultivating and supporting innovation. Wi2 is closely aligned with the University of Wisconsin-Madison (UW-Madison), a global leader in life science research and technology development. Wi2 provides a flexible and collaborative operating model for inventors and investors seeking to advance potentially life-saving technologies.